Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors

被引：2

作者：

Schoenfeld, David A. ^{[1
,2
,3
]}

机构：

[1] Massachusetts Gen Hosp, Biostat Ctr, 50 Staniford St, Boston, MA 02114 USA

[2] Harvard Med Sch, Dept Med, 401 Pk Dr,Suite 22 West, Boston, MA 02115 USA

[3] Harvard TH Chan Sch Publ Hlth, Dept Biostat, 677 Huntington Ave, Boston, MA 02115 USA

来源：

DRUGS | 2017年 / 77卷 / 10期

关键词：

D O I：

10.1007/s40265-017-0760-y

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1137 / 1138

页数：2

共 50 条

[1] Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
David A. Schoenfeld
Drugs, 2017, 77 : 1137 - 1138
[2] Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
Michiels, Stefan
Saad, Everardo D.
Buyse, Marc
DRUGS, 2017, 77 (07) : 713 - 719
[3] Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
Stefan Michiels
Everardo D. Saad
Marc Buyse
Drugs, 2017, 77 : 713 - 719
[4] Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors"
Michiels, Stefan
Saad, Everardo D.
Buyse, Marc
DRUGS, 2017, 77 (10) : 1139 - 1140
[5] Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors”
Stefan Michiels
Everardo D. Saad
Marc Buyse
Drugs, 2017, 77 : 1139 - 1140
[6] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
Stewart, D.
Bosse, D.
Ocana, A.
Goss, G.
Jonker, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
[7] Progression-free survival as a surrogate for overall survival in advanced cancer.
Gillies, Eric
Holdai, Veera
Cowall, David Eric
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.
Woodford, Rachel
Zhou, Deborah
Kok, Peey-Sei
Lord, Sally
Marschner, Ian
Friedlander, Michael
Lee, Chee Khoon
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] OVERALL SURVIVAL VERSUS PROGRESSION-FREE SURVIVAL IN ONCOLOGY CLINICAL TRIALS
Aissaoui, A.
Bin Sawad, A.
Turkistani, F.
Aissaoui, N.
VALUE IN HEALTH, 2016, 19 (07) : A717 - A717
[10] Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Korn, Ronald L.
Crowley, John J.
CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2607 - 2612

← 1 2 3 4 5 →